… fenofibric acid in the context of results from recent randomized trials on fenofibrate, including
the ACCORD Trial. It discusses the current status of fenofibric acid … opinion: fenofibric acid in …

… in patients with primary hyperlipidemia or mixed dyslipidemia; … hydrophilic choline salt of
fenofibric acid also can be taken … of fenofibrate and fenofibric acid that are currently available …

… -induced paw oedema rodent model, fenofibric acid exhibited relatively potent anti-… Hence,
we conclude that fenofibric acid and fenofibrate are not only anti-hyperlipidemic but also …

… Ellen and McPherson evaluated 80 patients with combined hyperlipidemia and either
known CAD or with 3 or more risk factors. They received low-dose statin (pravastatin 20 mg or …

… Additionally, fenofibric acid monotherapy reduced those … The previously mentioned
studies have resulted in fenofibric acid becoming the sole fibrate FDA … Fenofibric acid’s …

… HDL-C in patients with mixed hyperlipidemia and CHD or CHD risk equivalents who are
on … -C in patients with primary hyperlipidemia or mixed hyperlipidemia. Trilipix delayed-release …

… that is the choline salt of fenofibric acid. This agent is unique in that it dissociates to free
fenofibric acid within the gastrointestinal tract, allowing fenofibric acid to be rapidly and directly …

… is also indicated as monotherapy (as an adjunct to dietary therapy) in the treatment of patients
with severe hypertriglyceridemia, primary hyperlipidemia, or mixed dyslipidemia;[10] these …

… fenofibric acid monotherapy and statin monotherapy. Over 2000 patients with mixed
hyperlipidemia (… The arms consisted of two combination arms of fenofibric acid 135 mg with low- or …

… diabetes patients with combined hyperlipidemia, in which the … ) in patients with combined
hyperlipidemia was more effective … of a new formulation of fenofibric acid, choline fenofibrate, in …